Edition:
United States

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

26.48USD
10:33am EST
Change (% chg)

$1.38 (+5.50%)
Prev Close
$25.10
Open
$25.75
Day's High
$27.28
Day's Low
$25.75
Volume
34,644
Avg. Vol
65,467
52-wk High
$40.56
52-wk Low
$19.85

Latest Key Developments (Source: Significant Developments)

Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko
Thursday, 7 Dec 2017 05:20pm EST 

Dec 7 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK).REATA SAYS THIRD SUPPLEMENT ALLOWS CO TO BEGIN PORTION OF PHASE 3 CLINICAL STUDY OF RTA 402 IN FIELD OF ALPORT SYNDROME IN JAPAN - SEC FILING.REATA PHARMACEUTICALS - ON DEC 7 CO ENTERED FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO & KHK.  Full Article

Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​
Monday, 13 Nov 2017 09:18am EST 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc ::Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing.  Full Article

Reata Pharmaceuticals Q3 loss per share $0.50
Monday, 13 Nov 2017 07:30am EST 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc :Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results.Q3 loss per share $0.50.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Reata Pharmaceuticals Inc - qtrly ‍total collaboration revenue $12.6 million versus $12.6 million.Reata Pharmaceuticals Inc - ‍as of September 30, 2017, company had $154.6 million in cash and cash equivalents​.  Full Article

Reata Pharmaceuticals enters first amendment to loan and security agreement​
Tuesday, 7 Nov 2017 08:39am EST 

Nov 7 (Reuters) - Reata Pharmaceuticals Inc :Reata Pharmaceuticals says ‍on November 3, co entered into a first amendment to loan and security agreement​ - SEC filing.Reata Pharmaceuticals Inc - ‍loan agreement was amended to increase amount of term B loan to $20 million prior to term B loan increase milestone​.Reata Pharmaceuticals Inc - ‍agreement was amended to increase amount of term B loan to $25 million following term B loan increase milestone​.  Full Article

Reata Pharmaceuticals says top-line data to be available in 2019 for omaveloxolone​
Monday, 23 Oct 2017 07:30am EDT 

Oct 23 (Reuters) - Reata Pharmaceuticals Inc -:Reata Pharmaceuticals Inc - ‍announces first patient enrolled in Part 2 of Moxie study of omaveloxolone for treatment of Friedreich's Ataxia​.Reata Pharmaceuticals Inc - Reata expects top-line data to be available in second half of 2019 for omaveloxolone​ ‍​.  Full Article

Reata Pharma receives orphan drug designation for Omaveloxolone
Wednesday, 13 Sep 2017 05:26pm EDT 

Sept 13 (Reuters) - Reata Pharmaceuticals Inc :Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma.Reata Pharmaceuticals Inc - ‍FDA granted orphan designation to Omaveloxolone for treatment of stage IIb through IV malignant melanoma​.  Full Article

Reata Pharmaceuticals Q2 loss per share $0.52
Monday, 14 Aug 2017 04:01pm EDT 

Aug 14 (Reuters) - Reata Pharmaceuticals Inc :Reata pharmaceuticals Inc announces second quarter 2017 financial and operating results.Q2 loss per share $0.52.Q2 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.  Full Article

FDA confirms use of mFARS as main goal in MOXIe trial can support omaveloxolone approval in Friedreich’s Ataxia
Monday, 14 Aug 2017 07:00am EDT 

Aug 14 (Reuters) - Reata Pharmaceuticals Inc :FDA confirms that use of mFARS as primary endpoint in part 2 of the MOXIe trial can support approval of omaveloxolone in Friedreich’s Ataxia.Says ‍primary endpoint of trial will be change from baseline in mFARS of omaveloxolone compared to placebo at 48 weeks​.Reata Pharmaceuticals Inc says ‍initiated screening patients for part 2 of MOXIe and plans to randomize first patient during second half of 2017​.Reata Pharmaceuticals - ‍FDA indicated that it may consider either accelerated or full approval based on overall results of trial and strength of data​.Reata pharma- FDA recommended co extend treatment duration for part 2 of study, add a straightforward patient-reported or performance-based outcome endpoint.  Full Article

Reata announces first patient enrolled in Phase 3 Cardinal trial of Bardoxolone Methyl in the treatment of chronic kidney disease due to Alport Syndrome
Monday, 7 Aug 2017 05:15pm EDT 

Aug 7 (Reuters) - Reata Pharmaceuticals Inc :Reata announces first patient enrolled in phase 3 cardinal trial of Bardoxolone Methyl in the treatment of chronic kidney disease due to Alport Syndrome.  Full Article

William Rose reports 15.4 percent stake in Reata Pharmaceuticals Inc as on Aug 1
Wednesday, 2 Aug 2017 06:31am EDT 

Aug 2 (Reuters) - Reata Pharmaceuticals Inc :William Rose reports 15.4 percent stake in Reata Pharmaceuticals Inc as on Aug 1 - SEC filing‍​.William Rose had previously reported 18.9 percent stake in Reata Pharmaceuticals Inc as on July 10.  Full Article

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)